Literature DB >> 9667767

Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.

F Petitet1, B Jeantaud, M Reibaud, A Imperato, M C Dubroeucq.   

Abstract

Delta9-tetrahydrocannabinol (delta9-THC), cannabinol and cannabidiol are three important natural cannabinoids from the Marijuana plant (Cannabis sativa). Using [35S]GTP-gamma-S binding on rat cerebellar homogenate as an index of cannabinoid receptor activation we show that: delta9-THC does not induce the maximal effect obtained by classical cannabinoid receptor agonists such as CP55940. Moreover at high concentration delta9-THC exhibits antagonist properties. Cannabinol is a weak agonist on rat cerebellar cannabinoid receptors and cannabidiol behaves as an antagonist acting in the micromolar range.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667767     DOI: 10.1016/s0024-3205(98)00238-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  49 in total

Review 1.  Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Cell Mol Life Sci       Date:  2018-05-08       Impact factor: 9.261

Review 2.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 3.  Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

Authors:  John M McPartland; Marnie Duncan; Vincenzo Di Marzo; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-02       Impact factor: 8.739

4.  Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer's Disease.

Authors:  David Schubert; Devin Kepchia; Zhibin Liang; Richard Dargusch; Joshua Goldberg; Pamela Maher
Journal:  Mol Neurobiol       Date:  2019-05-19       Impact factor: 5.590

Review 5.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

Authors:  T V Zanelati; C Biojone; F A Moreira; F S Guimarães; Sâmia R L Joca
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

Review 7.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

8.  Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors.

Authors:  William H Hind; Timothy J England; Saoirse E O'Sullivan
Journal:  Br J Pharmacol       Date:  2016-02-03       Impact factor: 8.739

9.  Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.

Authors:  Carol A Paronis; Spyros P Nikas; Vidyanand G Shukla; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2012-12       Impact factor: 2.293

10.  Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats.

Authors:  Jennifer E Murray; Nicole R Wells; George D Lyford; Rick A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2009-06-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.